The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer.
Edward Jae-hoon Kim
Disclosure not yet available
Edgar Ben-Josef
Disclosure not yet available
Kent A. Griffith
Disclosure not yet available
Joseph M. Herman
Disclosure not yet available
Christopher Lee Wolfgang
Disclosure not yet available
Tanios S. Bekaii-Saab
Disclosure not yet available
Mark Bloomston
Disclosure not yet available
Laura A. Dawson
Disclosure not yet available
Malcolm J. Moore
Disclosure not yet available
Mark M. Zalupski
Disclosure not yet available